Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Tool Detects Breast Cancer Relapses Five Years in Advance

By LabMedica International staff writers
Posted on 23 Jun 2025

Relapse detection in patients with solid tumors—particularly hormone receptor-positive (HR+) breast cancer—remains a major clinical challenge, as many patients initially respond well to treatment but later relapse without early warning signs. More...

Traditional diagnostic methods often fail to detect these relapses in time due to limited sensitivity. Now, a new blood-based tool offers a minimally invasive solution that can identify signs of relapse months—sometimes years—before symptoms become clinically detectable.

The innovation, by Altum Sequencing (Madrid, Spain), a start-up supported by the C3N-IA Science Park at Universidad Carlos III de Madrid (UC3M, Getafe, Spain), aims to transform post-treatment follow-up in solid tumors by leveraging advanced sequencing technologies. At the tool's core is the use of next-generation sequencing (NGS) to analyze circulating tumor DNA (ctDNA)—small fragments of tumor-derived DNA found in the blood. The process starts with an initial biopsy to identify patient-specific mutations. Subsequent blood tests monitor for these specific mutations, allowing the detection of even one tumor cell among a million healthy ones. By concentrating only on mutations relevant to each patient, the approach enhances precision while reducing costs and the likelihood of false positives. The study, published in Breast Cancer Research, showed that the technology could detect clinical relapses in HR+ breast cancer patients up to 68 months before conventional diagnostic methods would typically identify them.

Given that up to 40% of patients with this subtype of breast cancer eventually relapse, this early detection window could dramatically alter patient outcomes by initiating timely intervention. The solution is not only personalized and highly sensitive but also broadly applicable across various types of solid tumors, thanks to its adaptable methodology. Its minimally invasive nature makes it ideal for regular monitoring, avoiding unnecessary treatments, and enhancing patient comfort. Altum is currently pursuing regulatory approvals in both Europe and the United States, aiming to bring this technology to hospitals worldwide. Looking ahead, the company is also planning to integrate generative artificial intelligence into its platform. Having already implemented machine learning algorithms to enhance diagnostics, Altum now seeks to further boost diagnostic accuracy, treatment customization, and delivery of actionable patient information through the use of AI.

"We started with hematological cancers such as multiple myeloma and acute myeloid leukemia, but we are already seeing good results in lung cancers as well, so our goal is to transform cancer monitoring," said Marina Planas, CEO of Altum Sequencing. “Today, we can detect one cell in a million. In the future, it will be one in ten million.”

Related Links:
Altum Sequencing
UC3M


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.